Question 1

How does the HemoTypeSC test work compared to traditional methods?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Evaluation of HemoTypeSC as a Novel Rapid Test for Point-of-Care Screening for Sickle-Cell Disease, Hemoglobin C Disease, and Carrier Status in Low-Resource Settings clinical trial (NCT03619798). Contact the study team or your healthcare provider for specific answers.

Question 2

What are the benefits of participating in this study?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Evaluation of HemoTypeSC as a Novel Rapid Test for Point-of-Care Screening for Sickle-Cell Disease, Hemoglobin C Disease, and Carrier Status in Low-Resource Settings clinical trial (NCT03619798). Contact the study team or your healthcare provider for specific answers.

Question 3

Are there any risks or side effects associated with the test?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Evaluation of HemoTypeSC as a Novel Rapid Test for Point-of-Care Screening for Sickle-Cell Disease, Hemoglobin C Disease, and Carrier Status in Low-Resource Settings clinical trial (NCT03619798). Contact the study team or your healthcare provider for specific answers.

Question 4

How will the results be shared and what do they mean for my health?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Evaluation of HemoTypeSC as a Novel Rapid Test for Point-of-Care Screening for Sickle-Cell Disease, Hemoglobin C Disease, and Carrier Status in Low-Resource Settings clinical trial (NCT03619798). Contact the study team or your healthcare provider for specific answers.

Question 5

What happens if the test shows a positive result for sickle cell disease?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Evaluation of HemoTypeSC as a Novel Rapid Test for Point-of-Care Screening for Sickle-Cell Disease, Hemoglobin C Disease, and Carrier Status in Low-Resource Settings clinical trial (NCT03619798). Contact the study team or your healthcare provider for specific answers.

Evaluation of HemoTypeSC as a Novel Rapid Test for Point-of-Care Screening for Sickle-Cell Disease, Hemoglobin C Disease, and Carrier Status in Low-Resource Settings

What this study is about

Evaluation of HemoTypeSC as a Novel Rapid Test for Point-of-Care Screening for Sickle-Cell Disease, Hemoglobin C Disease, and Carrier Status in Low-Resource Settings

What this study is about